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An enzyme-linked immunosorbent assay (ELISA) was established for the rapid detection of specific bovine
immunodeficiency virus (BIV) antibodies in cattle, using recombinant Gag protein as an antigen. The gag
coding region from BIV was cloned into an expression vector, pQE32, which expressed high levels of recombinant protein from Escherichia coli. The ELISA was standardized by a checkerboard titration against known
BIV-positive and -negative sera from cattle and a monoclonal antibody to the Gag protein. A total of 139 cattle
serum samples, from the diagnostic laboratory at Kansas State University, Manhattan, and from the Dairy
Station, Louisiana State University, Baton Rouge, were compared by ELISA and immunoblot assays for the
detection of BIV-specific antibodies. Of 26 cattle sera samples which tested positive using the immunoblot
assay, 23 were positive by ELISA, thus establishing a strong correlation between the two tests. The sensitivity
and specificity of ELISA relative to immunoblotting were 0.88 and 0.93, respectively. ELISA proved to be as
specific as immunoblotting but was much less time-consuming and easier to perform.
The BIV genome has been cloned, and the complete nucleotide sequence has been determined (5). Among the structural
proteins predicted by the nucleotide and amino acid sequences
of BIV is the core protein encoded by the gag gene. The Gag
precursor of BIV has been shown to have a molecular mass of
53 kDa (17), and, by analogy to HIV cleavage products, it is
predicted to be processed into three smaller proteins, p17, p26,
and p15 (10, 14), which are the matrix, capsid, and nucleocapsid proteins, respectively. Immune sera from calves experimentally infected with purified BIV detected p26 proteins in immunoblot analysis (25). This suggested that p26 is the major
core, or capsid, protein of BIV. Thus, the gag gene product is
an important viral antigen that induces a strong immune response in infected cattle. Recently, a purified recombinant BIV
Gag protein was used in an immunoblot assay to detect BIV
antibodies in field bovine serum samples (29). The method
proved to be sensitive and specific by comparing the results
with PCR (29). However, the immunoblotting is tedious and
time-consuming. In addition, the recombinant Gag protein was
expressed in pATH10 system as a TrpE fusion protein (3). The
TrpE fusion protein accounts for more than 50% of the recombinant protein. Since calves are exposed to a variety of
bacterial infections, the large proportion of fusion protein
gives high background reactivity. Therefore, the fusion proteins may not be suitable to be used as an enzyme-linked
immunosorbent assay (ELISA) antigen. Furthermore, the expressed level of Gag fusion protein in the pATH10 is relatively
low, and it is difficult to purify required amounts of the specific
protein. The present study was undertaken to express recombinant Gag protein in higher quantities and to develop an
ELISA for the diagnosis of BIV infection.

Bovine immunodeficiency virus (BIV) is a lentivirus that
causes lymphadenopathy, lymphocytosis, central nervous system lesions, progressive weakness, and emaciation (20, 21, 24).
Studies have shown that BIV resembles human immunodeficiency virus (HIV) type 1 and other lentiviruses, e.g., equine
infectious anemia virus and feline immunodeficiency virus, in
its structural, genetic, antigenic, and biological properties (5, 6,
16). Although BIV has been characterized in detail molecularly (5, 6, 7, 11, 15), little is known about the biology of
naturally occurring BIV infection. There has been no confirmed evidence of association of BIV infection with a naturally
occurring disease condition. However, BIV infection was reported to be associated with decreased lymphocytic blastogenic
response (12) and milk production (13). A possible immune
dysfunction in BIV-infected calves, with a drop in CD4/CD8
ratio and a decrease in antibody response to virus vaccines, was
also reported (27). Progress in the development of rapid tests
for diagnosis of BIV in cattle has been slow because of the
inability to generate adequate amounts of BIV antigens required for seroepidemiological studies. BIV can be propagated
well only in primary bovine cell cultures, and there is a lack of
availability of continuous cell lines expressing high levels of
BIV. The yields of native viral protein from primary bovine cell
culture are quite low (24), and those proteins show a high
background reactivity with negative control sera in serological
tests (25). Thus, there is a need for recombinant BIV antigens
to facilitate studying the epidemiology and prevalence of BIV
antibodies.
* Corresponding author. Mailing address: Department of Diagnostic Medicine-Pathobiology, College of Veterinary Medicine, 1800
Denison Ave., Kansas State University, Manhattan, KS 66506. Phone:
(785) 532-4603. Fax: (785) 532-4039. E-mail: Minocha@vet.ksu.edu.
† Contribution 99-55-J from the Kansas Agriculture Experiment
Station.

MATERIALS AND METHODS
Construction of prokaryotic BIV expression plasmids. For expression of BIV
in Escherichia coli, the pATH gag-3 clone, containing 781 bp of the gag coding
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FIG. 1. BIV gag construct. The thick horizontal bars represent the relative
genomic organizations of the gag, pol, and env coding regions of BIV. The large
open box represents the unprocessed p53gag precursor protein. The Gag precursor is processed into three smaller proteins: matrix (MA), capsid (CA), and
nucleocapsid (NC). Only the 751-bp capsid region was cloned into pQE32 vector.
BCAF, BIV capsid forward primer; BCAR, BIV capsid reverse primer; LTR,
long terminal repeat.

region, was used as a PCR template to generate a 751-bp gag product (Fig. 1).
The 5⬘ primer (GGATCCAGGCCAGAGCTGATAAGGAA) corresponded to
nucleotides (nt) 644 to 664 in the BIV genome, with a BamHI site added at the
beginning (underlined). The 3⬘ primer, AAGCTTATCCCACTACCCTACATG
CT, corresponded to nt 1375 to 1395 in the BIV genome, with a HindIII site
added (underlined). PCR amplification with these primers left the BamHI and
HindIII restriction sites at the ends of the product. pQE32, a modified version of
pDS56RBSII, a prokaryotic expression vector that uses the T5 promoter and two
lac operator sequences, was used to express the BIV gag cDNA. The pQE32
vector was replicated in a bacterial strain, E. coli M15, which expresses a high
level of the cloned gene under control of the lac repressor, permitting induction
of recombinant protein expression by isopropyl-␤-D-thiogalactoside (IPTG).
pQE32-gag was constructed by ligating the PCR product into a T vector by a
standard ligation procedure (19). Subsequently, the PCR product, digested with
BamHI and HindIII, was cloned into pQE32 using the same enzymes. The two
restriction sites enabled the cloning of the gag cDNA in the correct orientation,
ensuring translation in frame. The gag cDNA sequence at the junction region in
pQE32-gag was determined by the dideoxyribonucleotide chain termination
method (19).
Expression and purification of recombinant Gag protein. The construct was
maintained in E. coli M15, and expression of the Gag protein was induced with
2 mM IPTG for 4 h. E. coli strain M15 transformed with a pQE32 expression
vector containing the BIV gag gene, or transformed with plasmid pQE32 alone
as a negative control, was grown in 1.5 ml of Luria-Bertani broth containing both
ampicillin and kanamycin overnight at 37°C. The cultures were then inoculated
with fresh Luria-Bertani broth (1:4 dilution) and incubated for 30 min at 37°C.
IPTG was added to a final concentration of 2 mM to induce protein expression.
After 4 h of induction, cells were harvested by centrifugation at 4,000 ⫻ g for 15
min and lysed by sonication in lysis buffer B (8 M urea, 0.1 M NaH2PO4, 0.01 M,
and Tris-HCl, pH 8.0). The recombinant Gag proteins were analyzed by sodium
dodecyl sulfate–12.5% polyacrylamide gel electrophoresis (SDS–12.5% PAGE)
and purified by using Ni-nitrilotriacetic acid (Ni-NTA) columns (the polyhistidine tag at the amino terminus of the recombinant Gag protein binds to Ni-NTA
resin) (Pierce, Rockford, Ill.). The purified-protein concentration was determined by a dye-binding protein assay (Pierce). The Gag protein was then aliquoted and stored at ⫺20°C until use.
Immunoblot assay. Purified recombinant Gag protein was used as the antigen
in the immunoblot assay. The protein was loaded onto a preparative SDS–12.5%
PAGE minigel (Bio-Rad, Hercules, Calif.) and electrophoresed in Tris-glycine
buffer (0.025 M Tris base, 0.192 M glycine, 0.1% SDS) at 30 mA/gel for 1 h. The
protein was then transferred onto a nitrocellulose membrane (0.45-m pore size)
with a transblot apparatus (Bio-Rad) at 259 mA for 1 h. The membrane was
blocked with 2% bovine serum albumin–0.02 M Tris base–0.385 M NaCl–0.1%
Tween 20 (pH 7.5) (TTBS) at room temperature for 2 h, rinsed three times with
TTBS, and then cut into 5-mm strips (each strip contained 0.1 g protein).
Unknown and control sera were diluted 1:50 with TTBS in multichannel incubation trays, and the strips were put into each channel and incubated overnight
at 4°C. After being washed three times with TTBS, the strips were incubated with
horseradish peroxidase-labeled goat anti-bovine immunoglobulin G (IgG)
(heavy plus light chains) (1:3,000) (Kirkegaard & Perry Laboratories, Gaithersburg, Md.) for another 2 h at room temperature and rinsed twice with TTBS and
once with TBS (0.02 M Tris base, 0.385 M NaCl, pH 7.5). Finally, the color was
developed with a 4-CN substrate solution (100 ml of TBS, 60 l of H2O2, 20 ml
of ice-cold methanol, and 60 g of 4-chloronaphthol [Pierce]) at room temperature for 15 min.
Sera from calves either naturally or experimentally infected with BIV and a
monoclonal antibody to BIV Gag protein (27, 28) were included as positive
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controls in the experiment. Known calf sera negative for BIV and calf sera
positive for either bovine viral diarrhea virus (BVDV) or bovine herpesvirus 1
were also included as negative controls in the experiment.
ELISA. Preliminary titration experiments were conducted to determine optimum reagent concentrations using specific monoclonal antibodies and known
positive and negative control bovine sera. Immulon-I microtiter plates (Dynatech
Laboratories, Chantilly, Va.) were coated with purified recombinant Gag protein
(0.4 g/well). The antigens were diluted in 0.05 M sodium carbonate buffer (pH
9.6), and a 100-l volume was added to each well and incubated at 4°C overnight.
After coating, the microtiter plates were washed with 0.01 M phosphate-buffered
saline (PBS)–Tween 20 (0.05%) (PBST) buffer, blocked with 0.05% glycine in
PBS (100 l/well), and incubated at 37°C for 30 min. Test sera, diluted 1:50 in
PBST, were added to three wells (100 l/well) and incubated at 37°C for 30 min.
Control sera were twofold serially diluted, from 1:50 to 1:200, and tested against
the antigen. After five washes with PBST buffer, 100 l of a 1:5,000 dilution of
peroxidase-conjugated rabbit anti-bovine IgG or goat anti-mouse IgG (Kirkegaard & Perry Laboratories) in PBST was added to each well, and the plates were
incubated at 37°C for 30 min. The plates were then washed with PBST buffer,
followed by the addition of 100 l of ABTS [2,2⬘-azinobis(3-ethylbenzthiazolinesulfonic acid)] substrate (Kirkegaard & Perry Laboratories) to each well. The
plates were incubated at 37°C for 30 min. The absorbance was measured at 410
nm, and the cutoff value was based on the average optical density (OD) of the
negative control.
PCR. Sample DNA was extracted from the clotted bovine blood sample.
Briefly, after removal of the serum, the clotted blood was vigorously washed with
PBS, and blood cells released from the clot were collected. After centrifugation,
the pelleted blood cells were suspended with DNA extraction buffer A (100 mM
KCl, 10 mM Tris [pH 8.3], 2.5 mM MgCl2) and then incubated with an equal
volume of extraction buffer B (10 mM Tris [pH 8.3], 2.5 mM MgCl2, 1% NP-40,
120 g of proteinase K per ml) at 60°C for 1 h. DNA was then extracted with a
phenol-chloroform solution, followed by precipitation with isopropanol. After
washing with 70% alcohol and air drying, DNA was suspended in distilled water
and the DNA concentration was determined. DNAs from bovine blood samples
and BIV-positive and BIV-negative control DNAs were amplified by PCR using
a pair of primers designed to target a 242-bp highly conserved BIV pol gene.
Thermal cycling was performed using a 35-cycle profile of 95°C for 1 min, 50°C
for 1 min, and 72°C for 1 min (29). The PCR products were analyzed by 1.2%
agarose gel electrophoresis.
Field samples. Forty bovine serum samples with clotted blood (from Kansas)
were submitted to the Veterinary Diagnostic Laboratory, College of Veterinary
Medicine, Kansas State University, during 1999. Most of the cattle were clinically
normal, and the samples were submitted for routine serological tests. Another 99
serum samples were obtained from the Louisiana Agricultural Experiment Station, Baton Rouge Dairy Station.
Statistical analysis. A statistical analysis was performed on the data using the
SAS system. McNemar’s test was applied to the results that differed between the
ELISA and immunoblot methods.

RESULTS
Cloning, sequencing, and expression in E. coli of BIV Gag
protein. One 751-bp gag gene, corresponding to nt 644 to 1395
of the BIV genome, was made by PCR amplification (Fig. 1)
and subcloned into the prokaryotic expression vector pQE32,
designated pQE32-gag, for the production of Gag protein.
pQE32-gag was sequenced across the fusion junction to ensure
preservation of the reading frame. The sequence results (data
not shown) indicated that the recombinant 29-kDa Gag protein contains only 13 amino acids from the bacterial part, which
accounts for 5% of the total protein. After electrophoresis and
Coomassie blue staining, a distinct 29-kDa Gag-specific band
was observed in the bacterial lysates containing pQE32-gag
after IPTG induction (Fig. 2a, lane 2). The observed molecular
mass was in agreement with the predicted molecular mass of 29
kDa from the construct. The protein was purified by using
Ni-NTA columns and is shown as one band in SDS-PAGE
(Fig. 2a, lane 3). The total cellular protein from a clone containing the plasmid, pQE32, served as the negative control
(Fig. 2a, lane 1). The recombinant protein constituted approximately 25% of the total protein after IPTG induction. The
final yield of the fusion protein was about 1,500 g/ml of
bacterial culture (data not shown).
Immunoblot detection of Gag proteins. In order to test the
reactivities of the expressed Gag protein, immunoblot analysis
was carried out using a monoclonal antibody against Gag pro-
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FIG. 2. SDS-PAGE with Coomassie blue staining and immunoblot analysis
of pQE32-expressed Gag protein. Aliquots of induced proteins from pQE32
(lanes 1) and from pQE32-gag before (lanes 2) and after (lanes 3) purification
were subjected to SDS–12.5% PAGE. (a) Coomassie blue-stained gel. The arrow
indicates the 29-kDa Gag protein. (b) Immunoblot analysis of Gag protein.
Molecular masses in kilodaltons are given for markers at the left.

tein and two known naturally infected and immunized sera.
The immune serum was obtained from an animal immunized
against BIV (27, 28). Production of monoclonal antibody
against gag was described previously (27, 28). The monoclonal
antibody specifically recognized a 29-kDa Gag protein in
IPTG-induced, pQE32-gag-transformed bacterial extracts and
purified Gag protein (Fig. 2b, lanes 2 and 3). The absence of
any reactive band in the lysate containing pQE32 plasmid
alone indicated that the reaction is specific for the BIV antigen
(Fig. 2b, lane 1). During antigen titration, 0.2 g of purified
recombinant BIV Gag protein on 5-mm strips produced a
sharp band with all of the antibody dilutions of BIV-positive
sera. The BIV Gag protein showed a strong and specific reaction with sera collected from calves naturally and experimentally infected with BIV (Fig. 3, lanes 1 and 2). Normal serum
and two known BIV-negative sera did not recognize the Gag
protein (Fig. 3, lanes 3, 4, and 5). Control sera with antibodies
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to other bovine viruses, e.g., BVDV and bovine leukemia virus
(BLV), did not react with the BIV Gag protein (Fig. 3, lanes 6
and 7). Representative BIV-positive samples (lanes 8 and 9)
and BIV-negative samples (lanes 10 and 11) were also included. The minor band below the 29 kDa in lane 2 may result
from the degradation product of Gag protein.
Optimization of ELISA using recombinant Gag protein.
Preliminary titration experiments were conducted to determine optimum reagent concentrations and Immulon plates
using specific monoclonal antibodies and known BIV-positive
and -negative bovine sera. The most optimal and consistent
results were obtained when 0.4 g of Gag protein was used to
coat each wall of the Immulon I plate. Sample concentrations
were determined by standard checkerboard titration, using 0,
1:50, 1:100, and 1:200 dilutions, with the 1:50 dilution found to
be optimal based on the best signal-to-noise ratio. Samples
were run in triplicate; the greatest outlier OD reading was
discarded, and the remaining two values were averaged to give
an adjusted OD reading for each sample. This was done for
each positive and negative control for each run. The greatest
outlier OD reading being discarded was determined based on
the coefficient of variation (CV). If the CV for the OD reading
in each sample was greater than 5%, the OD reading was
discarded. If all the three CVs for each sample were within 5%,
the OD reading with the largest CV was discarded. Signal-topositive ratios for each sample were determined according to
the following formula used in the Kansas State University
diagnostic laboratory (26a): (adjusted ODsample ⫺ adjusted
ODnegative)/(adjusted ODpositive ⫺ adjusted ODnegative).
In order to establish a positive cutoff point, the adjusted
ODs of the negative controls were averaged and compared
with the average adjusted ODs of all positive controls, according to the formula [(average adjusted ODnegative)/(average adjusted ODpositive ⫺ average adjusted ODnegative)] ⫻ 2, which
gave a cutoff of 0.76 with a 95% lower confidence limit. Samples were judged to be positive if the sample signal-to-positive
ratio was equal or greater than 0.76. Using this cutoff value, the
ELISA results for 139 samples were obtained. The comparison
of the results with those obtained by immunoblotting are summarized in Table 1. A total of 139 samples from Kansas State
University and Louisiana State University were tested by both
ELISA and immunoblotting. The number of positive samples
as determined by both tests was 23, and the number of negative
samples by both tests was 105. Three samples were positive by
immunoblotting but negative by ELISA, while eight samples
positive by ELISA were negative by immunoblotting. All BIVpositive samples by immunoblotting were confirmed by PCR
(data not shown). Using standard formulas (23) to determine
sensitivity and specificity, immunoblot results were treated as
the true status. Sensitivity and specificity using immunoblot as
the true status can be calculated according to the following
equations: sensitivity ⫽ A/(A ⫹ C) and specificity ⫽ D/(B ⫹
D), where A is the number of samples ELISA positive and
immunoblot positive, B is the number ELISA positive and
immunoblot negative, C is the number ELISA negative and
immunoblot positive, and D is the number ELISA negative and
immunoblot negative. With values for A, B, C, and D of 23, 8,
3, and 105, respectively, the sensitivity equals 88% and the
specificity equals 93%. A statistical analysis was performed on
the data sets using McNemar’s method. McNemar’s test asked
whether the results of the ELISA and immunoblotting were
different, and no significant difference was found at the P level
of 0.10. In conclusion, the two methods agreed with each other.
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FIG. 3. Immunoblot analysis using BIV Gag protein as the antigen and probing with serum from cattle naturally infected with BIV (1:100) (lane 1), serum from
cattle experimentally infected with BIV (1:100) (lane 2), sera from one normal calf and two non-BIV-infected calves (1:20) (lanes 3, 4, and 5), BVDV- and BLV-positive
sera (1:20) (lanes 6 and 7), representative tested BIV-positive serum samples (1:100) (lanes 8 and 9), and tested BIV-negative serum samples (lanes 10 and 11).
Molecular mass standards in kilodaltons are given for markers at the left. The arrow indicates a BIV-specific band.

DISCUSSION
BIV infection is prevalent worldwide, and seropositive cattle
have been identified in many countries (1, 4, 7, 8, 9, 13, 22).
Although there were no reports on direct associations of BIV
infection and naturally occurring disease among cattle, there
were also no large-scale surveys on the prevalence and distribution of BIV among cattle. The lack of large surveys for BIV
was due partly to the difficulty in obtaining large amounts of
BIV antigen for the test. In order to develop a rapid diagnostic
test for BIV antibodies in bovine serum, we cloned the p26
Gag protein from BIV strain R29 and developed an ELISA
using the recombinant Gag protein as an antigen for detection
of BIV antibody.
As a potential diagnostic tool, a recombinant-protein-based
ELISA for BIV infection offers many advantages over other
methods. Using recombinant Gag protein as an antigen for
diagnosis of BIV will eliminate the use of native viral protein,
which is difficult to produce. High levels of protein expression
are attainable in a prokaryotic expression system contributing
to the purity of the final antigen preparation, thus improving
the specificity of the immunoassay. The recombinant Gag protein expressed in this study proved to be a very sensitive and
specific reagent for screening for BIV infection. The BIVspecific nature of this reactivity is confirmed by the absence of
reactivity seen in immune sera from animals infected with
other bovine viruses, such as BVDV and BLV.
The Gag protein was chosen as the antigen for a variety of
reasons. BIV Gag protein is highly immunogenic and contains
sequences that are conserved among the lentiviruses. It has
been demonstrated that Gag protein elicited an early, strong,
and long-lasting immune response in cattle (25, 26). Antibodies to BIV Gag protein can be detected as early as 2 weeks
after BIV infection and can last for at least 2 years. The
recombinant Gag protein expressed in E. coli presents epitopes
similar to those of the native viral protein and could be recognized specifically by sera from BIV-infected and -immunized
animals. Based on sequence analysis of the BIV gag coding
region, there are no obvious glycosylated sites (5). Therefore,
it is unlikely that the mature Gag protein is glycosylated in
vivo.

The gag gene from BIV has been cloned into a baculovirus
expression system (17), but the protein expressed had a relatively low yield. Recently, the gag gene was expressed as a TrpE
fusion protein in E. coli (3), and the protein yield was still
relatively low. The bacterial part of the fusion protein in the
TrpE system accounts for 50% of the total which might create
problems for ELISA. The Gag protein expressed here was
shown to be expressed at very high level, and the protein was
purified to be near homogeneity as evidenced by a single band
in Coomassie blue-stained gels (Fig. 2). Furthermore, the bacterial fusion part only accounts for 5% of the total protein,
which greatly increased the specificity of the recombinant Gag
protein used as an antigen in immunoassay.
Western blotting was the most widely used method to evaluate serological evidence of BIV in cattle serum samples (29).
The Western blot assay was considered to be sensitive and
reliable because its results were confirmed by PCR (29), and
the Western blot method was chosen as the classic reference
test in diagnosis of HIV infection (18). In this study, an ELISA
method was developed for detection of BIV antibody in serum
samples and its results were compared with those obtained by
Western blotting. Ten known BIV-positive and -negative serum samples were tested for BIV antibodies using the two
methods, which gave consistent results. However, there were
some discrepancies for the field serum samples tested using the
two methods (Table 1). There were eight ELISA-positive samples which were Western blot negative and three ELISA-negative samples which were Western blot positive. Those eight
positive samples were considered weakly positive samples by
ELISA because they had signal cutoff values of around 0.76 to
0.78, which was near the lower limit for positive samples (0.76).
At the 90% confidence limit, those samples were considered to
be negative. The three ELISA-negative samples had signal
cutoff values of around 0.73, which were near the upper limit
for the negative sample. At the 99% confidence limit, those
samples were considered to be positive. All 11 samples were
considered to be indeterminate by ELISA. These differences
could be due in part to differences in test sensitivity. Generally,
ELISA is more sensitive than Western blotting because it
needs a relatively smaller amount of antigen in testing. The
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TABLE 1. ELISA and immunoblotting results
Sample

ELISA result

Immunoblot result

Sample

ELISA result

Immunoblot result

Sample

ELISA result

Immunoblot result

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫹
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫹
⫺
⫺
⫺
⫺

⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫹
⫹
⫺
⫺
⫺

48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94

⫹
⫺
⫺
⫺
⫹
⫺
⫹
⫹
⫹
⫺
⫺
⫺
⫺
⫺
⫹
⫹
⫹
⫺
⫺
⫹
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫹
⫺
⫺

⫹
⫺
⫺
⫺
⫹
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫹
⫺
⫺
⫹
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫹
⫺

95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139

⫺
⫺
⫹
⫺
⫺
⫺
⫹
⫹
⫺
⫺
⫺
⫹
⫹
⫹
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫹
⫹
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺

⫺
⫺
⫹
⫺
⫺
⫹
⫹
⫹
⫺
⫺
⫺
⫹
⫹
⫹
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫹
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫺
⫹
⫺
⫺
⫺
⫺
⫺
⫺

a

Samples 1 to 40 were from Kansas State University, and samples 41 to 139 were from Louisiana State University.

differences may be caused by the presence of other closely
related retrovirus antibodies in field serum samples which may
interfere with the BIV test. Since BIV is closely related to
other retroviruses, antibodies against other retroviruses in serum samples might give false-positive results in Western blot
and ELISA tests. A PCR test could overcome this problem by
using unique primers designed for BIV. Since isolation of BIV
from samples is very difficult, there is no way to confirm the
true status of BIV infection. Thus, a combination of three
assays, i.e., ELISA, Western blotting, and PCR, was necessary
in order to confirm the indeterminate ELISA profiles. According to the recommendations of the World Health Organization, a combination of three tests is recommended for diagnostic testing for HIV (2). In HIV testing, a combination of
three assays was reported to be necessary to avoid false-positive results (2).

In conclusion, the expressed protein has been used successfully as an antigen for ELISA. The ELISA established here is
shown to be as specific as immunoblotting, and it has the
advantage of being less time-consuming and thus more economical. Therefore, it provides a better means than the currently available serological tests to study BIV antibody status in
cattle herds.
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